Skip to main content

CORCEPT THERAPEUTICS INC

For the period ended Jun 30, 2024. Filed Jul 29, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Jul 29, 2024

CORT$73.35-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · AdditionalPaid-inCapital · Treasury Stock · AccumulatedOtherComprehensiveIncome (Loss) · Retained Earnings · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2023103,405$133$738,515$(635,078)$609$402,526$506,705
Issuance of common stock under incentive award plan786—3,485———3,485
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(143)—2,032(5,586)——(3,554)
Repurchase of common stock in connection with Stock Repurchase Program(20)——(476)——(476)
Excise tax related to net share repurchases———81——81
Stock-based compensation——12,929———12,929
Vesting of RSAs in connection with ESPP——1,283———1,283
Other comprehensive loss, net of tax————(351)—(351)
Net income—————27,76227,762
Balance at March 31, 2024104,028$133$758,244$(641,059)$258$430,288$547,864
Issuance of common stock under our incentive award plan70017,573———7,574
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(208)——(6,242)——(6,242)
Repurchase of common stock in connection with Stock Repurchase Program(122)——(3,478)——(3,478)
Excise tax related to net share repurchases———16——16
Stock-based compensation——13,881———13,881
Vesting of RSAs in connection with ESPP——1,314———1,314
Other comprehensive loss, net of tax————(174)—(174)
Net income—$—$—$—$—$35,488$35,488
Balance at June 30, 2024104,398$134$781,012$(650,763)$84$465,776$596,243
Common Stock · AdditionalPaid-inCapital · Treasury Stock · AccumulatedOtherComprehensiveIncome (Loss) · Retained Earnings · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2022107,835$131$662,342$(456,148)$(869)$296,386$501,842
Issuance of common stock under incentive award plan618—6,540———6,540
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises(297)——(6,359)——(6,359)
Stock-based compensation——10,966———10,966
Other comprehensive income, net of tax————716—716
Net income—————15,87915,879
Balance at March 31, 2023108,156$131$679,848$(462,507)$(153)$312,265$529,584
Issuance of common stock under incentive award plan1,16814,496———4,497
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises(202)——(4,823)——(4,823)
Repurchase of common stock in connection with Tender Offer(6,610)——(145,428)——(145,428)
Excise tax related to net share repurchases———(1,316)——(1,316)
Stock-based compensation——11,374———11,374
Other comprehensive income, net of tax————198—198
Net income—————27,52827,528
Balance at June 30, 2023102,512$132$695,718$(614,074)$45$339,793$421,614

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.